| Stock Name | 泰德医药 |
|---|---|
| Stock Code | 03880 |
| Company Full Name | 泰德医药 |
| Industry | 醫療保健 |
| Principal Activities | 公司主要提供(i)CRO服務，即多肽NCE發現合成；及(ii)CDMO服務，即多肽CMC開發以及商業化生產。 |
| Listing Date | 2025-06-30 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國浙江省杭州市錢塘區12號大街69號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.medtideinc.com/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 30.60 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2025-06-20 to 2025-06-25 |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 15.3% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 257,040,000 |
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 100 | HK$ 3,060 |
| 2 lots | 200 | HK$ 6,120 |
| 3 lots | 300 | HK$ 9,180 |
| 4 lots | 400 | HK$ 12,240 |
| 5 lots | 500 | HK$ 15,300 |
| 6 lots | 600 | HK$ 18,360 |
| 7 lots | 700 | HK$ 21,420 |
| 8 lots | 800 | HK$ 24,480 |
| 9 lots | 900 | HK$ 27,540 |
| 10 lots | 1,000 | HK$ 30,600 |
| 15 lots | 1,500 | HK$ 45,900 |
| 20 lots | 2,000 | HK$ 61,200 |
| 25 lots | 2,500 | HK$ 76,500 |
| 30 lots | 3,000 | HK$ 91,800 |
| 35 lots | 3,500 | HK$ 107,100 |
| 40 lots | 4,000 | HK$ 122,400 |
| 45 lots | 4,500 | HK$ 137,700 |
| 50 lots | 5,000 | HK$ 153,000 |
| 60 lots | 6,000 | HK$ 183,600 |
| 70 lots | 7,000 | HK$ 214,200 |
| 80 lots | 8,000 | HK$ 244,800 |
| 90 lots | 9,000 | HK$ 275,400 |
| 100 lots | 10,000 | HK$ 306,000 |
| 200 lots | 20,000 | HK$ 612,000 |
| 300 lots | 30,000 | HK$ 918,000 |
| 400 lots | 40,000 | HK$ 1,224,000 |
| 500 lots | 50,000 | HK$ 1,530,000 |
| 600 lots | 60,000 | HK$ 1,836,000 |
| 700 lots | 70,000 | HK$ 2,142,000 |
| 800 lots | 80,000 | HK$ 2,448,000 |
| 900 lots | 90,000 | HK$ 2,754,000 |
| 1,000 lots | 100,000 | HK$ 3,060,000 |
| 1,500 lots | 150,000 | HK$ 4,590,000 |
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 2,000 lots | 200,000 | HK$ 6,120,000 |
| 2,500 lots | 250,000 | HK$ 7,650,000 |
| 3,000 lots | 300,000 | HK$ 9,180,000 |
| 3,500 lots | 350,000 | HK$ 10,710,000 |
| 4,000 lots | 400,000 | HK$ 12,240,000 |
| 4,500 lots | 450,000 | HK$ 13,770,000 |
| 5,000 lots | 500,000 | HK$ 15,300,000 |
| 6,000 lots | 600,000 | HK$ 18,360,000 |
| 7,000 lots | 700,000 | HK$ 21,420,000 |
| 8,400 lots | 840,000 | HK$ 25,704,000 |
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
| First Day Close | HK$ 30.8 |
|---|---|
| First Day Open | HK$ 30.3 |
| First Day Change | 0.65% |
| First Day Volume | 8593800.0 |
| First Day Turnover | 272301000.0 |
| Use of Proceeds | 1、約76.4%（或314.0百萬港元）將用于在美國及中國建設設施以進一步擴大公司服務能力及產能； 2、約4.1%（或16.9百萬港元）將用于擴張中國的產能； 3、約9.5%（或39.2百萬港元）將用于在更多地區建立銷售及售后服務網點，以豐富公司全球業務及擴大公司客戶群； 4、約10.0%（或41.1百萬港元）將用于公司營運資金及其他一般公司用途。 |
|---|
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Welight Capital L.P. | 39,244,500 HKD | — | 7.63% | — | 6 months | 2025-12-30 |
| 2 | 佳曦控股有限公司 | 39,244,500 HKD | — | 7.63% | — | 6 months | 2025-12-30 |
| Chairman | 徐琪 |
|---|---|
| Company Secretary | 李玲梅,吳東澄 |
| Major Shareholders & Holdings | 琪康國際有限公司(42.01%),杭州海鼎科技有限公司(10.87%),李湘莉(7.24%),衢州海邦肽達創業投資合伙企業(有限合伙)及杭州海邦博源創業投資合伙企業(有限合伙)(6.69%) |
|---|
Market Sentiment
The IPO of Tede Medicine (03880) attracted substantial retail interest, with an oversubscription ratio of 301.15 times across 70,338 valid applications, indicating vigorous demand. However, the reported hit rate of 0.0% appears anomalous given the high oversubscription and likely stems from incomplete source data. The reallocation trigger and clawback to Tier C further confirm strong retail enthusiasm. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier Analysis
Tier distribution details are unavailable in the provided data, making precise anomaly analysis impossible. With mechanism Type A (old) and Clawback Tier C triggered, it is common for the boundary between 甲尾 and 乙头 to be narrow, but no specific lot sizes or winner ratios are available to confirm inefficiencies or compare broker fee efficiency across tiers. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Demographics
Demographic data is entirely missing, with total holders, mainland participation, and Hong Kong percentages all recorded as zero. In similarly oversubscribed IPOs, mainland Chinese investors often dominate, but here no conclusions can be drawn about age, gender, or regional concentration like Guangdong. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
